Two main factors that affect the pharmacokinetics of cyclosporin A (CsA) during 24-h durable intravenous (DIV) administration have been reported, namely physiological changes after bone marrow transplantation, and blood sampling through indwelling lines. In addition, it has been found that infusion sets made of polyvinyl chloride (PVC) markedly adsorb CsA. We conducted in vitro adsorption studies of CsA on infusion sets, and the administration routes that are used in the treatment of patients with bone marrow transplantation. We also examined the effects of administration route on CsA pharmacokinetics in clinical practice. The in vitro adsorption study using 30-mm segments of lumen from commercially available infusion sets showed that the degree of CsA adsorption per area of lumen made of PVC was significantly higher than that in those made of polyethylene (PE) or polybutadiene (PB), which showed no adsorption of CsA. Due to its adsorption, use of infusion sets made of PVC resulted in about a 40-50% loss of CsA dose, which affected the pharmacokinetic parameters during 24-h DIV, while those made of PE and PB did not. The use of non-PVC infusion sets should allow for accurate monitoring of CsA results, and provide cost benefit in the treatment of bone marrow transplantation. Bone Marrow Transplantation (2000) 25, 633-638.
Summary:
Two main factors that affect the pharmacokinetics of cyclosporin A (CsA) during 24-h durable intravenous (DIV) administration have been reported, namely physiological changes after bone marrow transplantation, and blood sampling through indwelling lines. In addition, it has been found that infusion sets made of polyvinyl chloride (PVC) markedly adsorb CsA. We conducted in vitro adsorption studies of CsA on infusion sets, and the administration routes that are used in the treatment of patients with bone marrow transplantation. We also examined the effects of administration route on CsA pharmacokinetics in clinical practice. The in vitro adsorption study using 30-mm segments of lumen from commercially available infusion sets showed that the degree of CsA adsorption per area of lumen made of PVC was significantly higher than that in those made of polyethylene (PE) or polybutadiene (PB), which showed no adsorption of CsA. Due to its adsorption, use of infusion sets made of PVC resulted in about a 40-50% loss of CsA dose, which affected the pharmacokinetic parameters during 24-h DIV, while those made of PE and PB did not. The use of non-PVC infusion sets should allow for accurate monitoring of CsA results, and provide cost benefit in the treatment of bone marrow transplantation. Bone Marrow Transplantation (2000) 25, 633-638. Keywords: cyclosporin; administration route; bone marrow transplantation; adsorption; immunosuppressive therapy; therapeutic drug monitoring Cyclosporin A (CsA), an immunosuppressant given intravenously or orally, has been shown to be effective in the prevention of graft-versus-host disease (GVHD) after allogenic bone marrow transplantation. [1] [2] Due to the narrow therapeutic range of CsA, blood concentration monitoring is advocated to avoid toxicity and to obtain optimal immunosuppression. 3 However, the measurements of CsA in whole blood show marked variations within and between Correspondence: N Shibata at his present address: Department of Pharmacokinetics, Kyoto Pharmaceutical University, Nakauchi-cho 5, Misasagi Yamashina-ku, Kyoto 607-8414, Japan Received 23 April 1999; accepted 23 September 1999 patients. It has been reported that there are two main factors influencing the pharmacokinetics of CsA in bone marrow transplants, ie disease state-dependent changes in the pharmacokinetics of CsA, 4 and complications arising from blood sampling of CsA via the administration route. 5 Busca et al 5 warned that blood sampling through indwelling lines (Hickman catheters, placed in the right atrium) indicated false elevation of the blood CsA concentration. Therefore, they recommended that blood samples should be obtained from the second lumen of the catheter or peripheral veins for accurate monitoring of blood CsA concentrations. 5 In addition, it has been reported that several infusion sets made of polyvinyl chloride (PVC), widely used in clinical settings, adsorb CsA. 6 Therefore, it is expected that administration routes using infusion sets made of PVC will affect the concentration of CsA in blood, and its pharmacokinetics.
In this study, we investigated the in vitro adsorption of CsA in infusion sets made of PVC , and the effects of administration routes using them on the amount of CsA remaining in the infusion solution. Moreover, we developed an administration route made of non-PVC material for 24-h durable intravenous administration, and evaluated clinical use of this route in bone marrow transplant patients.
Materials and methods

Reagents and infusion sets
CsA for injection (Sandimmun) was purchased from Novartis Pharma (Basel, Switzerland). Five percent glucose solution in polyethylene bottles (250 ml or 500 ml) was purchased from Otsuka Pharmaceuticals (Tokyo, Japan). Commercially available infusion sets as listed in Table 1 were used in this study. Two infusion sets (TS-PA300L41, TS-PA304L) for pumping tubes made of PVC and polybutadiene (PB) were purchased from Terumo, and three infusion sets for extension tubes made of PVC (PT48, 2C6631) and polyethylene (PE) (JV-EN100L) were purchased from OMEDA (WI, USA), Baxter (IL, USA) and JMS (Hiroshima, Japan), respectively. All other chemicals were of analytical grade, and were used without further purification. 
In vitro adsorption tests
According to the method of Nakajima et al 7 with some modifications, 30-mm segments of lumens from different infusion sets were incubated for various times in 50-ml screw-capped test tubes with 10 ml of CsA test solution at room temperature (21 Ϯ 1°C). The CsA test solution was prepared by diluting Sandimmun in 5% glucose solution to a final concentration of 0.5 mg/ml.
Plasticizer contents in infusion sets made of PVC
The contents of plasticizer, ie diethylhexylphthalate, in the infusion sets made of PVC were measured by HPLC according to Nakajima et al. 8 
Adsorption to administration routes
We prepared three administration routes using the commercially available infusion sets listed in Table 1 (Table 2) for exclusive use in bone marrow transplantation. The total lengths of the administration routes of CsA (Route 1, Route 2, Route 3) were 5.15 to 5.90 m via a peristaltic finger pump (Terumo, Tokyo, Japan) as illustrated in Figure 1 .
The lengths of these administration routes of CsA were convenient for patients living in a clean room after bone marrow transplantation. The CsA test solutions were prepared by diluting Sandimmun in 5% glucose solution to concentrations of 0.5 and 1 mg/ml. The flow rates for respective test solutions were set at 20 ml/h and 10 ml/h. CsA concentrations at the inlet and outlet were measured at the times indicated after the start of the infusion, and the remaining percentages of CsA and adsorption rate were calculated. In clinical practice, the extreme point of the administration route was linked to the indwelling line, and blood samples at steady-state were obtained from an elbow vein.
Adaptation of administration routes to patients
Three patients (males, aged 20 to 59) who underwent bone marrow transplantation were enrolled into this study. All patients received bone marrow transplantation from a related donor. Clinical details of these patients are listed in Table 3 . The original diseases in Patients A, B and C were acute lymphocytic leukemia (ALL), acute myelocytic leu- kemia (AML) and aplastic anemia (AA). There were no differences in the body mass index (BMI) or creatinine clearance (CCr) among the patients, but the hematocrit for Patient C was slightly lower than that of the other patients. Patient A with ALL was conditioned with cytarabine, cyclophosphamide and total body irradiation. Patient B with AML was conditioned with cyclophosphamide, and Patient C with AA was conditioned with cyclophosphamide and anti-human thymocyte immunoglobulin (hare). All patients received a combination of CsA and methotrexate as GVHD prophylaxis: 24-h DIV of CsA was started at a dose of 3 mg/kg/day from day −1, and the concentration of CsA at steady-state was maintained at 400 ng/ml until the patient was released from aseptic conditions and able to receive oral CsA. Dosage adjustments of CsA were essentially made based on the CsA monitoring results of whole blood at steady-state.
Calculations
The apparent adsorption rate (AAR, g/h) to the lumen of the administration routes was determined by the following equation: AAR = Q(C in − C out ), where Q represents the flow rate of infusion solution, and C in and C out represent the concentration of CsA at the inlet and outlet, respectively. Total body clearance of CsA (CLt, l/h/kg) was calculated by the following pharmacokinetic equation: CLt = k 0 /C ss , where k 0 and C ss represent infusion rate (mg/h/kg) and CsA concentration at steady-state (ng/ml).
Assay and biochemical tests
The CsA concentrations in test solutions and whole blood were measured using a monoclonal-fluorescence polarization immunoassay (m-FPIA), and the TDx operation system (Abbott Laboratory Diagnostic Division, North Chicago IL, USA) according to the Abbott assay manual. 9 Calibration curves for test solutions were constructed from the net polarization values obtained by adding known amounts of CsA-free samples. Within-day and between-day precisions for the assay of test solutions at 500 ng/ml of CsA were within 5% and 7%, respectively. Hepatic function was assessed by alanine transaminase activity, total bilirubin and renal function were assessed by CCr calculated from serum creatinine using the equation of Cockcroft and Gault. 10 
Statistics
To examine the predictive performance for the fitting data, we calculated mean prediction error (ME), mean absolute prediction error (MAE) and route mean squared error (RMSE) according to the method of Sheiner et al.
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Results
In vitro adsorption of CsA into segments of various infusion sets
To determine the degree of adsorption of CsA into commercially available infusion sets, the amounts of CsA adsorbed
Bone Marrow Transplantation per area for 30-mm segments of lumen from these infusion sets were measured. Figure 2 shows the adsorption curves of CsA from time zero to after 48 h of incubation at room temperature, and the relationship between the amount of CsA absorbed per area after 48 h of incubation and the content of plasticizer, diethylhexylphthalate, in the segments of infusion sets made of PVC. The degree of adsorption of CsA per area for infusion sets made of PVC was higher than those for sets made of PE or PB (Figure 2a) . In addition, a significant linear relationship was found between the amount of CsA adsorbed per area after 48-h incubation and the content of diethylhexylphthalate in the PVC segments (P Ͻ 0.001), suggesting that the adsorption of CsA into the infusion sets made of PVC is dependent on the content of plasticizer (Figure 2b ). On the other hand, there was no adsorption to segments of lumens made of PE or PB. Figure 3 shows changes in the remaining percentages and apparent adsorption rates (AAR) after passage through the infusion routes via a peristaltic finger pump. In these experiments, effects of CsA concentration of the infusion solution and its flow rate on CsA adsorption were also investigated. There were two conditions for CsA concentration and flow rate: condition 1, 1 mg/ml CsA in 5% glucose with a flow rate of 10 ml/h; condition 2, 0.5 mg/ml CsA in 5% glucose with a flow rate of 20 ml/h. In condition 1 (Figure 3a, b) , the remaining percentage of CsA in the tubes made of PVC (Routes 1 and 2) was markedly decreased in comparison with that of Route 3, which consisted of PB and PE. Moreover, the AARs were markedly increased in the routes made of PVC. In condition 2 ( Figure 3c, d) , the remaining percentage and AAR were essentially the same as those in condition 1, but the remaining percentages of CsA increased with decreasing AAR. Throughout these experiments, the magnitude of adsorption of CsA to administration routes tested was in the order Route 1 Ͼ Route 2 Ͼ Route 3. When the AAR observed in Route 1 was extrapolated until the velocity reached zero, saturation in the adsorption of CsA was expected to occur at 48 h after pumping.
Changes in remaining percentages and adsorption rates for constructed infusion routes
Clinical adaptation of administration routes constructed for patients
Three administration routes of CsA constructed for this experiment were tested in three BMT patients. None of the patients had a history of nephrotoxicity or hepatotoxicity as determined by clinical laboratory tests, during the study period. The pharmacokinetic data during 24-h DIV administration of CsA for each patient are summarized in Table 4 .
In clinical practice, the pump tubes were changed every 24 h, and the extension tubes, every 7 days. The pumping conditions for CsA solution were: 1 mg/ml in 5% glucose solution with a flow rate of 10 ml/h for Patients A and B, and 0.5 mg/ml in 5% glucose solution with a flow rate of 20 ml/h. The mean dose of CsA for Patient A, in whom Route 1 made of PVC was used, was higher than those for the others. Coefficients of variation for the pharmacokinetic parameters, C ss and CL t in Patients A and B, in whom PVC routes were used, were larger than that in Patient C, in whom a non-PVC route constructed from infusion sets made of PB and PE was used. Moreover, based on the clinical results from these patients, we examined the predictive performance of C ss by fitting regression lines between the C ss measured and CL t calculated using the monitoring data. Although all linear regressions for the patients were significant, ME, MAE and RMSE for Patient C, in whom 637 Table 4 Pharmacokinetic parameters for patients with bone marrow transplantation treated by different infusion routes Route 3 made of non-PVC was used, were relatively small in comparison to those of Patients A and B, in whom tubes made of PVC were used.
Discussion
Busca et al 5 recommended that blood samples for CsA monitoring should be withdrawn from the second lumen of the catheter, or peripheral vein (exclusively for blood sampling for CsA monitoring) because blood sampling via the administration route led to misleading CsA measurements in whole blood. However, their study did not show the adsorption of CsA in relation to administration routes made of PVC. In this study, we found marked adsorption of CsA into administration routes consisting of customary infusion sets made of PVC. The infusion sets tested here were those available in our hospital, and therefore the results of this in vitro study do not reflect the differences in infusion sets between manufacturers. The extent of adsorption of CsA into administration routes made of PVC was influenced by a combination of CsA concentration in the infusion solution, the flow rate of the infusion solution, and infusion sets made of PVC. Moreover, we concluded that a periodic change of administration tubes is required when infusion sets made of PVC are used for the administration of CsA in bone marrow transplant patients, because there were vast differences in adsorption rates between administration routes.
After pumping of CsA solution (1.0 mg/ml in 5% glucose with a flow rate of 10 ml/h) by the peristaltic-finger pump, high levels of CsA precipitation were found within the PVC lumen adjacent to the peristaltic-finger portion of the infusion pump (data not shown). This observation indicated that the adsorption of CsA was excessive in this area because CsA solubility is temperature-dependent; ie higher temperature decreases solubility of CsA. 12 The peristaltic motion of the pump may elevate the temperature, and thus decrease the solubility of CsA in 5% glucose solution. The remaining curves shown in Figure 3 indicated that the rate of adsorption of CsA to Route 1 was very high, and may result in a 40 to 50% loss in CsA dose. In addition, we cannot exclude the possibility that if a lump of CsA precipitate is dislodged by vibration, the blood concentrations of CsA would increase rapidly. Therefore, use of administration routes made of PVC wastes the drug, and gives misleading pharmacokinetic results.
It has been pointed out that two main factors affect the pharmacokinetics of CsA, ie physiological changes after bone marrow transplantation and blood sampling through indwelling lines. Physiological factors include patient's age and sex, disease state, type of transplantation, coadministered drugs etc. 4 As listed in Table 4 , the reduction in the values of ME, MAE and RMSE for Patient C with Route 3, ie a non-PVC route, indicated that the least misleading pharmacokinetic which related to infusion route, was minimized. Using non-PVC administration routes consisting of infusion sets made of PB or PE, the adsorption of CsA to the lumen was markedly decreased, and the problems of variability in the CsA pharmacokinetics originating from CsA adsorption into the administration device can be avoided. The use of such administration devices will contribute to the design of CsA regimens based on the simplest clearance model, and provide cost benefit for therapy in patients undergoing bone marrow transplantation.
